Engineered mutant α-ENaC subunit mRNA delivered by lipid nanoparticles reduces amiloride currents in cystic fibrosis–based cell and mice models

Anindit Mukherjee,Kelvin D. MacDonald,Jeonghwan Kim,Michael I. Henderson,Yulia Eygeris,Gaurav Sahay

DOI: https://doi.org/10.1126/sciadv.abc5911

IF: 13.6

2020-11-20

Science Advances

Abstract:A nanoparticle delivered ENaC-inhibitory mRNA for the treatment of cystic fibrosis.

multidisciplinary sciences

What problem does this paper attempt to address?

Delivery of ENaC siRNA to epithelial cells mediated by a targeted nanocomplex: a therapeutic strategy for cystic fibrosis

Maria D. I. Manunta,Aristides D. Tagalakis,Martin Attwood,Ahmad M. Aldossary,Josephine L. Barnes,Mustafa M. Munye,Alexander Weng,Robin J McAnulty,Stephen L. Hart

DOI: https://doi.org/10.1038/s41598-017-00662-2

IF: 4.6

2017-04-06

Scientific Reports

Abstract:The inhibition of ENaC may have therapeutic potential in CF airways by reducing sodium hyperabsorption, restoring lung epithelial surface fluid levels, airway hydration and mucociliary function. The challenge has been to deliver siRNA to the lung with sufficient efficacy for a sustained therapeutic effect. We have developed a self-assembling nanocomplex formulation for siRNA delivery to the airways that consists of a liposome (DOTMA/DOPE; L), an epithelial targeting peptide (P) and siRNA (R). LPR formulations were assessed for their ability to silence expression of the transcript of the gene encoding the α-subunit of the sodium channel ENaC in cell lines and primary epithelial cells, in submerged cultures or grown in air-liquid interface conditions. LPRs, containing 50 nM or 100 nM siRNA, showed high levels of silencing, particularly in primary airway epithelial cells. When nebulised these nanocomplexes still retained their biophysical properties and transfection efficiencies. The silencing ability was determined at protein level by confocal microscopy and western blotting. In vivo data demonstrated that these nanoparticles had the ability to silence expression of the α-ENaC subunit gene. In conclusion, these findings show that LPRs can modulate the activity of ENaC and this approach might be promising as co-adjuvant therapy for cystic fibrosis.

multidisciplinary sciences
Highly Branched Poly Β-Amino Ester/cpg-Depleted CFTR Plasmid Nanoparticles for Non-viral Gene Therapy in Lung Cystic Fibrosis Disease

Bei Qiu,Dario Manzanares,Yinghao Li,Xianqing Wang,Zishan Li,Sebastien Terreau,Zhonglei He,Jing Lyu,Wenxin Wang,Irene Lara-Saez

DOI: https://doi.org/10.1016/j.omtm.2024.101292

2024-01-01

Abstract:Lung cystic fibrosis (CF) is a lethal inherited disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, leading to a dysfunctional CFTR protein. Gene therapy offers promise for the treatment of lung CF. However, the development and clinical application of CF gene therapy have long been hampered by the absence of safe and highly efficient delivery vectors. In this work, a novel polymer-based gene replacement treatment approach was developed. A series of poly (β-amino esters) (PAEs) with various topological structures and chemical compositions were screened to create non-viral therapeutic systems for CFTR restoration in lung CF disease. A nanoparticle, formed by the selected highly branched PAE (HPAE) with a CpG-depleted CFTR plasmid, demonstrated CFTR gene expression and biocompatibility in lung epithelial cells, outperforming leading commercial gene transfection reagents such as Lipofectamine 3000 and Xfect. The newly developed gene therapy system successfully restored functional CFTR protein production in lung CF epithelial monolayers. This therapeutic approach holds great potential for use as an efficient and safe non-viral treatment for CF patients.
Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis

A K M Ashiqul Haque,Alexander Dewerth,Justin S Antony,Joachim Riethmüller,Georg R Schweizer,Petra Weinmann,Ngadhnjim Latifi,Hanzey Yasar,Nicoletta Pedemonte,Elvira Sondo,Brian Weidensee,Anjali Ralhan,Julie Laval,Patrick Schlegel,Christian Seitz,Brigitta Loretz,Claus-Michael Lehr,Rupert Handgretinger,Michael S D Kormann

DOI: https://doi.org/10.1038/s41598-018-34960-0

2018-11-13

Abstract:Gene therapy has always been a promising therapeutic approach for Cystic Fibrosis (CF). However, numerous trials using DNA or viral vectors encoding the correct protein resulted in a general low efficacy. In the last years, chemically modified messenger RNA (cmRNA) has been proven to be a highly potent, pulmonary drug. Consequently, we first explored the expression, function and immunogenicity of human (h)CFTR encoded by cmRNAhCFTR in vitro and ex vivo, quantified the expression by flow cytometry, determined its function using a YFP based assay and checked the immune response in human whole blood. Similarly, we examined the function of cmRNAhCFTR in vivo after intratracheal (i.t.) or intravenous (i.v.) injection of the assembled cmRNAhCFTR together with Chitosan-coated PLGA (poly-D, L-lactide-co-glycolide 75:25 (Resomer RG 752 H)) nanoparticles (NPs) by FlexiVent. The amount of expression of human hCFTR encoded by cmRNAhCFTR was quantified by hCFTR ELISA, and cmRNAhCFTR values were assessed by RT-qPCR. Thereby, we observed a significant improvement of lung function, especially in regards to FEV0.1, suggesting NP-cmRNAhCFTR as promising therapeutic option for CF patients independent of their CFTR genotype.
Randomised, phase 1/2a trial of ION-827359, an antisense oligonucleotide inhibitor of ENaC

Sivagurunathan Sutharsan,Rainald Fischer,Wolfgang Gleiber,Alex Horsley,Jeff Crosby,Shuling Guo,Shuting Xia,Rosie Yu,Kenneth B Newman,J Stuart Elborn

DOI: https://doi.org/10.1183/23120541.00986-2023

2024-09-16

Abstract:Background: Hyperactivity of epithelial sodium channel (ENaC) with increased sodium absorption is a feature of cystic fibrosis (CF). ION-827359 is a 2.5-generation antisense oligonucleotide targeted to reduce ENaC protein. This study evaluated ION-827359 safety, pharmacokinetics and pharmacodynamics. Methods: In this three-part phase 1/2a, double-blind, randomised study, healthy volunteers received single doses of placebo or ION-827359 (3, 10, 37.5 or 100 mg; Part 1) or multiple doses of placebo or ION-827359 (5×10 mg, 5×37.5 mg, 5×75 mg or 10×37.5 mg; Part 2). People with CF (pwCF) received multiple doses of placebo or ION-827359 (5×10 mg, 5×37.5 mg, 5×75 mg and 5×100 mg; Part 3). Treatments were administered via Pari eFlow© mesh nebuliser. The primary outcome was safety; pharmacokinetic and pharmacodynamic parameters were also assessed. Results: 64 healthy volunteers and 34 pwCF were enrolled. ION-827359 was well tolerated with an acceptable safety profile. There were no clinically relevant changes in laboratory values, ECG or vital signs. Systemic drug exposure was low (plasma half-life ∼2 weeks). Multiple doses of ION-827359 were associated with dose-dependent reductions in ENaC mRNA in bronchial epithelium. After multiple dosing, forced expiratory volume in 1 s was slightly higher in pwCF receiving ION-827359 (+2.9% with ION-827359 100 mg versus placebo; p=0.27). Conclusions: The tolerability and safety of ION-827359 appear favourable at this stage of investigation. Reduction in ENaC mRNA supports mechanistic efficacy at the doses and regimens tested, and supports further investigation of ION-827359 in pwCF.
WS17.04 Developing a Non-Viral Gene Therapy Strategy for Treating Lung Cystic Fibrosis Disease

B. Qiu,D. Manzanares,X. Wang,Z. He,Y. Li,S. A,I. Lara-Sáez,W. Wang

DOI: https://doi.org/10.1016/s1569-1993(23)00280-1

IF: 5.527

2023-01-01

Journal of Cystic Fibrosis

Abstract:Objective: Currently there is no cure for cystic fibrosis (CF) disease and lung is the most affected organ [1Cooney A Gene. 2018 Nov; 9: 538Crossref Scopus (72) Google Scholar]. Gene replacement is a promising strategy to treat this disease. However, the two big challenges that have impeded its success are the absence of: (1) an efficient and safe gene delivery reagent to transfect the target cells, and (2) a stable plasmid that enables high and sustained CF transmembrane conductance regulator (CFTR) expression. Thus, the aim of this work is to develop a non-viral CFTR gene replacement system for lung CF disease to overcome these two challenges. Methods: A cationic highly branched poly(β-amino ester) (HPAE) polymer [2Zhou D Sci Adv. 2016 Jun; 6e160010Google Scholar] with high transfection efficiency was used as a non-viral gene delivery reagent complexed to a CpG-depleted CFTR plasmid with high and sustained CFTR expression and expected lower immune response to transfect CF lung epithelial cells in vitro. Results: By using the HPAE for CFTR gene delivery, similar gene expression and higher cell viability (~98%) than commercial transfection reagents such as Xfect™ (~77%) and Lipofectamine™ 3000 (~51%) were achieved after 48 hours. Moreover, around 2400% and 120% higher CFTR protein levels compared to healthy human lung epithelial cells were obtained after 48 hours and 7 days of transfection in CF lung epithelial cells, respectively. Conclusion: We developed a very promising HPAE/CFTR polyplex system as it is demonstrated that only 6–10% CFTR protein expression of healthy lung epithelial cells is enough to restore the ionic transport in CF lung epithelial cells [3Johnson L Nat Genet. 1992 Sep; 2: 21-25Crossref PubMed Scopus (382) Google Scholar]. In addition, a nebulization system for testing this HPAE/CFTR polyplex system in vivo by inhalation in mice is being currently developed. The expected results could potentially support the future use of this technology as a gene therapy for treating lung cystic fibrosis disease.
ENaC contributes to macrophage dysfunction in cystic fibrosis

John Moran,Courtney Pugh,Nevian Brown,Ashley Thomas,Shuzhong Zhang,Emily McCauley,Amelia Cephas,Chandra Shrestha,Santiago Partida-Sanchez,Shasha Bai,Emanuela M Bruscia,Benjamin Kopp

DOI: https://doi.org/10.1101/2024.11.06.622340

2024-11-08

Abstract:Background: Cystic fibrosis (CF) is a chronic systemic disease caused by dysfunctional or absent cystic fibrosis transmembrane conductance regulator (CFTR). CFTR is expressed in human immune cells and plays a role in regulating innate immunity both directly and indirectly. Besides CFTR, research indicates that the epithelial sodium channel (ENaC) also contributes to dysfunction in CF airway epithelial cells. However, the impact of non-CFTR ion channel dysfunction on CF immune responses is not yet fully understood. A precise understanding of how CF immune function is regulated by ion channels may allow antibiotic-and mutation-agnostic treatment approaches to chronic bacterial infection and inflammation. Therefore, we hypothesized that ENaC is aberrantly expressed in CF macrophages and directly contributes to impaired phagocytic and inflammatory functions. Methods: ENaC expression was characterized in human immune cells isolated from CF and non-CF blood donors. Monocyte-derived macrophage (MDM) function and bacterial killing was tested in the setting of ENaC modulation. Results: Baseline expression of ENaC in human CF MDMs, lymphocytes, and granulocytes was increased at both the transcript and protein level relative to non-CF controls and persisted after exposure to bacteria. Inhibition of CFTR in non-CF MDMs resulted in ENaC overexpression. CFTR modulator treatment reduced but did not eliminate ENaC overexpression in CF MDMs. Interestingly, ENaC inhibition with Amiloride increased CFTR expression. Amiloride-treated CF MDMs also showed normalized ROS production, improved autophagy, and decreased pro-inflammatory cytokine production. Finally, results from an ion channel microarray indicated that sodium channel expression in CF MDMs normalized after Amiloride treatment with minimal effect on other ion channels. Discussion: ENaC is overexpressed in CF immune cells and is associated with abnormal macrophage function. ENaC modulation in immune cells is a novel potential therapeutic target for infection control in CF, either in combination with CFTR modulators, or as a sole agent for patients not currently eligible for CFTR modulators.

Immunology
Gene-specific nonsense-mediated mRNA decay targeting for cystic fibrosis therapy

Young Jin Kim,Tomoki Nomakuchi,Foteini Papaleonidopoulou,Lucia Yang,Qian Zhang,Adrian R. Krainer

DOI: https://doi.org/10.1038/s41467-022-30668-y

IF: 16.6

2022-05-27

Nature Communications

Abstract:Abstract Low CFTR mRNA expression due to nonsense-mediated mRNA decay (NMD) is a major hurdle in developing a therapy for cystic fibrosis (CF) caused by the W1282X mutation in the CFTR gene. CFTR-W1282X truncated protein retains partial function, so increasing its levels by inhibiting NMD of its mRNA will likely be beneficial. Because NMD regulates the normal expression of many genes, gene-specific stabilization of CFTR- W1282X mRNA expression is more desirable than general NMD inhibition. Synthetic antisense oligonucleotides (ASOs) designed to prevent binding of exon junction complexes (EJC) downstream of premature termination codons (PTCs) attenuate NMD in a gene-specific manner. We describe cocktails of three ASOs that specifically increase the expression of CFTR- W1282X mRNA and CFTR protein upon delivery into human bronchial epithelial cells. This treatment increases the CFTR-mediated chloride current. These results set the stage for clinical development of an allele-specific therapy for CF caused by the W1282X mutation.

multidisciplinary sciences
Engineering Lipid Nanoparticles for Enhanced Intracellular Delivery of mRNA through Inhalation.

A. Jozić,Jeonghwan Kim,Kevin D. Welsher,G. Sahay,Xiaochen Tan,Elissa Bloom,K. MacDonald,Yuxin Lin,Chris Acosta,Yulia Eygeris

DOI: https://doi.org/10.1021/acsnano.2c05647

IF: 17.1

2022-08-29

ACS Nano

Abstract:Despite lipid nanoparticles' (LNPs) success in the effective and safe delivery of mRNA vaccines, an inhalation-based mRNA therapy for lung diseases remains challenging. LNPs tend to disintegrate due to shear stress during aerosolization, leading to ineffective delivery. Therefore, LNPs need to remain stable through the process of nebulization and mucus penetration, yet labile enough for endosomal escape. To meet these opposing needs, we utilized PEG lipid to enhance the surficial stability of LNPs with the inclusion of a cholesterol analog, β-sitosterol, to improve endosomal escape. Increased PEG concentrations in LNPs enhanced the shear resistance and mucus penetration, while β-sitosterol provided LNPs with a polyhedral shape, facilitating endosomal escape. The optimized LNPs exhibited a uniform particle distribution, a polyhedral morphology, and a rapid mucosal diffusion with enhanced gene transfection. Inhaled LNPs led to localized protein production in the mouse lung without pulmonary or systemic toxicity. Repeated administration of these LNPs led to sustained protein production in the lungs. Lastly, mRNA encoding the cystic fibrosis transmembrane conductance regulator (CFTR) was delivered after nebulization to a CFTR-deficient animal model, resulting in the pulmonary expression of this therapeutic protein. This study demonstrated the rational design approach for clinical translation of inhalable LNP-based mRNA therapies.

Medicine,Engineering
Anticodon Engineered Transfer RNAs (ACE-tRNAs) are a Platform Technology for Suppressing Nonsense Mutations

Wooree Ko,Joseph J. Porter,Sacha Spelier,Tyler Couch,Isabelle van der Windt,Priyanka Bhatt,Kevin Coote,Martin Mense,Jeffrey Beekman,John D. Lueck

DOI: https://doi.org/10.1101/2024.06.06.597760

2024-06-06

Abstract:Nonsense mutations arise from single nucleotide substitutions that result in premature termination codons (PTCs). PTCs result in little to no full-length protein production and loss of mRNA expression through the nonsense-mediated mRNA decay (NMD) pathway. We demonstrate that anticodon engineered (ACE-) tRNAs efficiently suppress the most prevalent cystic fibrosis (CF) causing PTCs, promoting significant rescue of endogenous cystic fibrosis transmembrane conductance regulator (CFTR) transcript abundance and channel function in different model systems. We demonstrate that our best-performing ACE-tRNA, that decodes all UGA PTCs to a leucine amino acid, markedly rescues CFTR channel function from the most prevalent CF causing PTCs that arise from non-leucine encoding codons. Using this single ACE-tRNA variant, we demonstrate significant rescue of CFTR channel function in an immortalized airway cell line and two different primary CF patient-derived intestinal cell models with CFTR nonsense mutations. Thus, ACE-tRNAs have promise as a platform therapeutic for CF and other nonsense-associated diseases.

Molecular Biology
Nanoparticles as Drug Delivery Vehicles for People with Cystic Fibrosis

Eoin Hourihane,Katherine R Hixon

DOI: https://doi.org/10.3390/biomimetics9090574

2024-09-22

Abstract:Cystic Fibrosis (CF) is a life-shortening, genetic disease that affects approximately 145,000 people worldwide. CF causes a dehydrated mucus layer in the lungs, leading to damaging infection and inflammation that eventually result in death. Nanoparticles (NPs), drug delivery vehicles intended for inhalation, have become a recent source of interest for treating CF and CF-related conditions, and many formulations have been created thus far. This paper is intended to provide an overview of CF and the effect it has on the lungs, the barriers in using NP drug delivery vehicles for treatment, and three common material class choices for these NP formulations: metals, polymers, and lipids. The materials to be discussed include gold, silver, and iron oxide metallic NPs; polyethylene glycol, chitosan, poly lactic-co-glycolic acid, and alginate polymeric NPs; and lipid-based NPs. The novelty of this review comes from a less specific focus on nanoparticle examples, with the focus instead being on the general theory behind material function, why or how a material might be used, and how it may be preferable to other materials used in treating CF. Finally, this paper ends with a short discussion of the two FDA-approved NPs for treatment of CF-related conditions and a recommendation for the future usage of NPs in people with Cystic Fibrosis (pwCF).
Ligand-free biodegradable poly(beta-amino ester) nanoparticles for targeted systemic delivery of mRNA to the lungs

Erin W Kavanagh,Stephany Y Tzeng,Neeraj Sharma,Garry R Cutting,Jordan J Green

DOI: https://doi.org/10.1016/j.biomaterials.2024.122753

IF: 14

2024-08-20

Biomaterials

Abstract:Non-viral nanoparticles (NPs) have seen heightened interest as a delivery method for a variety of clinically relevant nucleic acid cargoes in recent years. While much of the focus has been on lipid NPs, non-lipid NPs, including polymeric NPs, have the possibility of improved efficacy, safety, and targeting, especially to non-liver organs following systemic administration. A safe and effective systemic approach for intracellular delivery to the lungs could overcome limitations to intratracheal/intranasal delivery of NPs and improve clinical benefit for a range of diseases including cystic fibrosis. Here, engineered biodegradable poly (beta-amino ester) (PBAE) NPs are shown to facilitate efficient delivery of mRNA to primary human airway epithelial cells from both healthy donors and individuals with cystic fibrosis. Optimized NP formulations made with differentially endcapped PBAEs and systemically administered in vivo lead to high expression of mRNA within the lungs in BALB/c and C57 B/L mice without requiring a complex targeting ligand. High levels of mRNA-based gene editing were achieved in an Ai9 mouse model across bronchial, epithelial, and endothelial cell populations. No toxicity was observed either acutely or over time, including after multiple systemic administrations of the NPs. The non-lipid biodegradable PBAE NPs demonstrate high levels of transfection in both primary human airway epithelial cells and in vivo editing of lung cell types that are targets for numerous life-limiting diseases particularly single gene disorders such as cystic fibrosis and surfactant deficiencies.
Lipid nanoparticle-mediated mRNA delivery in lung fibrosis

Matteo Massaro,Suhong Wu,Gherardo Baudo,Haoran Liu,Scott Collum,Hyunho Lee,Cinzia Stigliano,Victor Segura-Ibarra,Harry Karmouty-Quintana,Elvin Blanco

DOI: https://doi.org/10.1016/j.ejps.2023.106370

IF: 5.112

2023-04-01

European Journal of Pharmaceutical Sciences

Abstract:mRNA delivery enables the specific synthesis of proteins with therapeutic potential, representing a powerful strategy in diseases lacking efficacious pharmacotherapies. Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by excessive extracellular matrix (ECM) deposition and subsequent alveolar remodeling. Alveolar epithelial type 2 cells (AEC2) and fibroblasts represent important targets in IPF given their role in initiating and driving aberrant wound healing responses that lead to excessive ECM deposition. Our objective was to examine a lipid nanoparticle (LNP)-based mRNA construct as a viable strategy to target alveolar epithelial cells and fibroblasts in IPF. mRNA-containing LNPs measuring ∼34 nm had high encapsulation efficiency, protected mRNA from degradation, and exhibited sustained release kinetics. eGFP mRNA LNP transfection in human primary cells proved dose- and time-dependent in vitro. In a bleomycin mouse model of lung fibrosis, luciferase mRNA LNPs administered intratracheally led to site-specific lung accumulation. Importantly, bioluminescence signal was detected in lungs as early as 2 h after delivery, with signal still evident at 48 h. Of note, LNPs were found associated with AEC2 and fibroblasts in vivo. Findings highlight the potential for pulmonary delivery of mRNA in IPF, opening therapeutic avenues aimed at halting and potentially reversing disease progression.

pharmacology & pharmacy
Multifunctional Natural Polymer Nanoparticles as Antifibrotic Gene Carriers for CKD Therapy

Adam C Midgley,Yongzhen Wei,Dashuai Zhu,Fangli Gao,Hongyu Yan,Anila Khalique,Wenya Luo,Huan Jiang,Xiangsheng Liu,Jiasen Guo,Chuangnian Zhang,Guowei Feng,Kai Wang,Xueyuan Bai,Wen Ning,Chao Yang,Qiang Zhao,Deling Kong,Adam C. Midgley

DOI: https://doi.org/10.1681/asn.2019111160

IF: 14.978

2020-08-07

Journal of the American Society of Nephrology

Abstract:Background Progressive fibrosis is the underlying pathophysiological process of CKD, and targeted prevention or reversal of the profibrotic cell phenotype is an important goal in developing therapeutics for CKD. Nanoparticles offer new ways to deliver antifibrotic therapies to damaged tissues and resident cells to limit manifestation of the profibrotic phenotype. Methods We focused on delivering plasmid DNA expressing bone morphogenetic protein 7 (BMP7) or hepatocyte growth factor (HGF)–NK1 (HGF/NK1) by encapsulation within chitosan nanoparticles coated with hyaluronan, to safely administer multifunctional nanoparticles containing the plasmid DNA to the kidneys for localized and sustained expression of antifibrotic factors. We characterized and evaluated nanoparticles in vitro for biocompatibility and antifibrotic function. To assess antifibrotic activity in vivo , we used noninvasive delivery to unilateral ureteral obstruction mouse models of CKD. Results Synthesis of hyaluronan-coated chitosan nanoparticles containing plasmid DNA expressing either BMP7 or NGF/NKI resulted in consistently sized nanoparticles, which—following endocytosis driven by CD44 + cells—promoted cellular growth and inhibited fibrotic gene expression in vitro . Intravenous tail injection of these nanoparticles resulted in approximately 40%–45% of gene uptake in kidneys in vivo . The nanoparticles attenuated the development of fibrosis and rescued renal function in unilateral ureteral obstruction mouse models of CKD. Gene delivery of BMP7 reversed the progression of fibrosis and regenerated tubules, whereas delivery of HGF/NK1 halted CKD progression by eliminating collagen fiber deposition. Conclusions Nanoparticle delivery of HGF/NK1 conveyed potent antifibrotic and proregenerative effects. Overall, this research provided the proof of concept on which to base future investigations for enhanced targeting and transfection of therapeutic genes to kidney tissues, and an avenue toward treatment of CKD.

urology & nephrology
Backbone cationized highly branched poly( β -amino ester)s as enhanced delivery vectors in non-viral gene therapy

Yinghao Li,Bei Qiu,Zishan Li,Xianqing Wang,Zhonglei He,Darío Manzanares Sandoval,Rijian Song,A. Sigen,Chunyu Zhao,Melissa Johnson,Jing Lyu,Irene Lara-Sáez,Wenxin Wang

DOI: https://doi.org/10.1016/j.jconrel.2024.01.046

IF: 11.467

2024-02-03

Journal of Controlled Release

Abstract:Gene therapy holds great potential for treating Lung Cystic Fibrosis (CF) which is a fatal hereditary condition arising from mutations in the CF transmembrane conductance regulator (CFTR) gene, resulting in dysfunctional CFTR protein. However, the advancement and clinical application of CF gene therapy systems have been hindered due to the absence of a highly efficient delivery vector. In this work, we introduce a new generation of highly branched poly( β -amino ester) (HPAE) gene delivery vectors for CF treatment. Building upon the classical chemical composition of HPAE, a novel backbone cationization strategy was developed to incorporate additional functional amine groups into HPAE without altering their branching degree. By carefully adjusting the type, proportion, and backbone distribution of the added cationic groups, a series of highly effective HPAE gene delivery vectors were successfully constructed for CF disease gene therapy. In vitro assessment results showed that the backbone cationized HPAEs with randomly distributed 10% proportion of 1-(3-aminopropyl)-4-methylpiperazine (E7) amine groups exhibited superior transfection performance than their counterparts. Furthermore, the top-performed backbone cationized HPAEs, when loaded with therapeutic plasmids, successfully reinstated CFTR protein expression in the CFBE41o- disease model, achieving levels 20–23 times higher than that of normal human bronchial epithelial (HBE) cells. Their therapeutic effectiveness significantly surpassed that of the currently advanced commercial vectors, Xfect and Lipofectamine 3000.

pharmacology & pharmacy,chemistry, multidisciplinary
Targeted Activation of Cystic Fibrosis Transmembrane Conductance Regulator

Olga Villamizar,Shafagh A Waters,Tristan Scott,Sheena Saayman,Nicole Grepo,Ryan Urak,Alicia Davis,Adam Jaffe,Kevin V Morris

DOI: https://doi.org/10.1016/j.ymthe.2019.07.002

2019-10-02

Abstract:Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. The majority of CFTR mutations result in impaired chloride channel function as only a fraction of the mutated CFTR reaches the plasma membrane. The development of a therapeutic approach that facilitates increased cell-surface expression of CFTR could prove clinically relevant. Here, we evaluate and contrast two molecular approaches to activate CFTR expression. We find that an RNA-guided nuclease null Cas9 (dCas9) fused with a tripartite activator, VP64-p65-Rta can activate endogenous CFTR in cultured human nasal epithelial cells from CF patients. We also find that targeting BGas, a long non-coding RNA involved in transcriptionally modulating CFTR expression with a gapmer, induced both strong knockdown of BGas and concordant activation of CFTR. Notably, the gapmer can be delivered to target cells when generated as electrostatic particles with recombinant HIV-Tat cell penetrating peptide (CPP), when packaged into exosomes, or when loaded into lipid nanoparticles (LNPs). Treatment of patient-derived human nasal epithelial cells containing F508del with gapmer-CPP, gapmer-exosomes, or LNPs resulted in increased expression and function of CFTR. Collectively, these observations suggest that CRISPR/dCas-VPR (CRISPR) and BGas-gapmer approaches can target and specifically activate CFTR.
Niclosamide - encapsulated lipid nanoparticles for the reversal of pulmonary fibrosis

Yan Yu,Hongyao Liu,Liping Yuan,Meng Pan,Zhongwu Bei,Tinghong Ye,Zhiyong Qian

DOI: https://doi.org/10.1016/j.mtbio.2024.100980

IF: 8.2

2024-04-01

Materials Today Bio

Abstract:Pulmonary fibrosis (PF) is a serious and progressive fibrotic interstitial lung disease that is possibly life-threatening and that is characterized by fibroblast accumulation and collagen deposition. Nintedanib and pirfenidone are currently the only two FDA-approved oral medicines for PF. Some drugs such as antihelminthic drug niclosamide (Ncl) have shown promising therapeutic potentials for PF treatment. Unfortunately, poor aqueous solubility problems obstruct clinical application of these drugs. Herein, we prepared Ncl-encapsulated lipid nanoparticles (Ncl-Lips) for pulmonary fibrosis therapy. A mouse model of pulmonary fibrosis induced by bleomycin (BLM) was generated to assess the effects of Ncl-Lips and the mechanisms of reversing fibrosis <i>in vivo</i>. Moreover, cell models treated with transforming growth factor β1 (TGFβ1) were used to investigate the mechanism through which Ncl-Lips inhibit fibrosis <i>in vitro</i>. These findings demonstrated that Ncl-Lips could alleviate fibrosis, consequently reversing the changes in the levels of the associated marker. Moreover, the results of the tissue distribution experiment showed that Ncl-Lips had aggregated in the lung. Additionally, Ncl-Lips improved the immune microenvironment in pulmonary fibrosis induced by BLM. Furthermore, Ncl-Lips suppressed the TGFβ1-induced activation of fibroblasts and epithelial-mesenchymal transition (EMT) in epithelial cells. Based on these results, we demonstrated that Ncl-Lips is an efficient strategy for reversing pulmonary fibrosis via drug-delivery.

engineering, biomedical,materials science, biomaterials
Intranasal Delivery and Transfection of mRNA Therapeutics in the Brain Using Cationic Liposomes.

Jonghan Kim,H. Dhaliwal,M. Amiji,Yingfang Fan

DOI: https://doi.org/10.1021/acs.molpharmaceut.0c00170

2020-05-04

Molecular Pharmaceutics

Abstract:Nucleic acid-based therapeutics, including the use of messenger-RNA (mRNA) as a drug molecule has tremendous potential in the treatment of chronic diseases, such as age-related neurodegenerative diseases. In this study, we have developed cationic liposomal formulation of mRNA and evaluated the potential of intranasal delivery to the brain in murine models. Preliminary in vitro studies in J774A.1 murine macrophages showed GFP expression up to 24 h and stably expressed GFP protein in the cytosol. Upon intranasal administration of GFP-mRNA/cationic liposomes (3 mg/kg dose), there was significantly higher GFP-mRNA expression in the brain post-24 h as compared to either naked mRNA or vehicle-treated group in mice. Luciferase mRNA encapsulated in cationic liposomes was used for quantification of expression in distribution in the brain. The results showed increased luciferase activity in the whole brain in a dose-dependent manner. Specifically, luciferase-mRNA/cationic liposome group (3 mg/kg dose) showed significantly higher luciferase activity in cortex, striatum, and midbrain regions as compared with the control groups, with minimal systemic exposure. Overall, the results of this study demonstrate the feasibility of brain-specific, non-viral mRNA delivery for the treatment of various neurological disorders.

Medicine,Chemistry
EGFP-EGF1-conjugated poly (lactic-co-glycolic acid) nanoparticles as a carrier for the delivery of CCR2− shRNA to atherosclerotic macrophage in vitro

Zhilin Wu,Chen Chen,Jiajia Luo,Jacques R. J. Davis,Bo Zhang,Liang Tang,Wei Shi,Danying Liao

DOI: https://doi.org/10.1038/s41598-020-76416-4

IF: 4.6

2020-11-12

Scientific Reports

Abstract:Abstract Reducing macrophage recruitment by silencing chemokine (C–C motif) receptor 2 (CCR2) expression is a promising therapeutic approach against atherosclerosis. However the transfection of macrophages with siRNA is often technically challenging. EGFP-EGF1-conjugated poly (lactic-co-glycolic acid) (PLGA) nanoparticles (ENPs) have a specific affinity to tissue factor (TF). In this study, the feasibility of ENPs as a carrier for target delivery of CCR2-shRNA to atherosclerotic cellular models of macrophages was investigated. Coumarin-6 loaded ENPs were synthesized using a double-emulsion method. Fluorescence microscopy and flow cytometry assay were taken to examine the uptake of Coumarin-6 loaded ENPs in the cellular model. Then a sequence of shRNA specific to CCR2 mRNA was constructed and encapsulated into ENPs. Target delivery of CCR2-shRNA to atherosclerotic cellular models of macrophages in vitro were evaluated. Results showed more uptake of ENPs by the cellular model than common PLGA nanoparticles. CCR2-shRNA loaded ENPs effectively silenced CCR2 gene in the atherosclerotic macrophages and exhibited a favorable cytotoxic profile to cultured cells. With their low cytotoxicity and efficient drug delivery, ENP could be a useful carrier for target delivery of CCR2-shRNA to inflammatory monocytes/macrophages for the therapy against atherosclerosis.

multidisciplinary sciences
Efficient mRNA delivery using lipid nanoparticles modified with fusogenic coiled-coil peptides

Ye Zeng,Mengjie Shen,Roy Pattipeiluhu,Xuequan Zhou,Yun Zhang,Thomas Bakkum,Thomas H Sharp,Aimee L Boyle,Alexander Kros,MengJie Shen,Thomas Sharp,alexander kros

DOI: https://doi.org/10.1039/d3nr02175k

IF: 6.7

2023-09-06

Nanoscale

Abstract:Gene delivery has great potential in modulating protein expression in specific cells to treat diseases. Such therapeutic gene delivery demands sufficient cellular internalization and endosomal escape. Of various nonviral nucleic acid delivery systems, lipid nanoparticles (LNPs) are the most advanced, but still, are very inefficient as the majority are unable to escape from endosomes/lysosomes. Here, we develop a highly efficient gene delivery system using fusogenic coiled-coil peptides. We modified LNPs, carrying EGFP-mRNA, and cells with complementary coiled-coil lipopeptides. Coiled-coil formation between these lipopeptides induced fast nucleic acid uptake and enhanced GFP expression. The cellular uptake of coiled-coil modified LNPs is likely driven by membrane fusion thereby omitting typical endocytosis pathways. This direct cytosolic delivery circumvents the problems commonly observed with the limited endosomal escape of mRNA. Therefore fusogenic coiled-coil peptide modification of existing LNP formulations to enhance nucleic acid delivery efficiency could be beneficial for several gene therapy applications.

materials science, multidisciplinary,physics, applied,nanoscience & nanotechnology,chemistry
Lipid-based nanoparticles deliver mRNA to reverse the pathogenesis of lysosomal acid lipase deficiency in a preclinical model

Matthias Zadory,Elliot Lopez-Vince,Hamza Haddouch,Samuel Babity,Nastaran Rezaei,Fatma Moawad,Rita Maria Kenaan El Rahbani,Nemanja Vujic,Dagmar Kratky,Simon-Pierre Gravel,Davide Brambilla

DOI: https://doi.org/10.1101/2024.12.07.627318

2024-12-08

Abstract:Lysosomal acid lipase (LAL) is the only known enzyme that degrades cholesteryl esters (CEs) and triglycerides (TGs) in the lysosomes. LAL deficiency (LAL-D) results in hepatosplenomegaly with extensive accumulation of CEs and TGs, and can in the most severe cases be a life-threatening condition in early infancy. Using messenger ribonucleic acid (mRNA) for protein replacement is an innovative approach for the treatment of genetic disorders, but is challenged by a safe and efficient mRNA delivery. Here, we generated a combinatorial library of lipid-based nanoparticles (LNPs) for mRNA delivery and screened it in vitro and in vivo, which yielded a new formulation with a superior potency than an FDA-approved nanoformulation. This formulation efficiently delivered LAL mRNA and restored LAL activity in liver and spleen, mediating significant reversal of the pathological progression in an aggressive preclinical model of LAL-D. In vivo, the new formulation also promoted a more sustained and quantitatively higher LAL expression. In addition, repeated administration regimen mitigated hepatosplenomegaly, and targeted lipidomic analysis revealed strong diminution of CEs and TGs and of toxic lipid species in the liver and spleen. Transcriptomic analysis showed significant attenuation of inflammatory processes, fibrosis and several pathological pathways associated to LAL-D. These findings provide strong evidence that the intracellular production of LAL via mRNA-LNP is a very promising approach for the chronic treatment of LAL-D and support the clinical translation of mRNA therapy to overcome the challenges associated with traditional enzyme replacement therapies.

Bioengineering

Engineered mutant α-ENaC subunit mRNA delivered by lipid nanoparticles reduces amiloride currents in cystic fibrosis–based cell and mice models

Delivery of ENaC siRNA to epithelial cells mediated by a targeted nanocomplex: a therapeutic strategy for cystic fibrosis

Highly Branched Poly Β-Amino Ester/cpg-Depleted CFTR Plasmid Nanoparticles for Non-viral Gene Therapy in Lung Cystic Fibrosis Disease

Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis

Randomised, phase 1/2a trial of ION-827359, an antisense oligonucleotide inhibitor of ENaC

WS17.04 Developing a Non-Viral Gene Therapy Strategy for Treating Lung Cystic Fibrosis Disease

ENaC contributes to macrophage dysfunction in cystic fibrosis

Gene-specific nonsense-mediated mRNA decay targeting for cystic fibrosis therapy

Engineering Lipid Nanoparticles for Enhanced Intracellular Delivery of mRNA through Inhalation.

Anticodon Engineered Transfer RNAs (ACE-tRNAs) are a Platform Technology for Suppressing Nonsense Mutations

Nanoparticles as Drug Delivery Vehicles for People with Cystic Fibrosis

Ligand-free biodegradable poly(beta-amino ester) nanoparticles for targeted systemic delivery of mRNA to the lungs

Lipid nanoparticle-mediated mRNA delivery in lung fibrosis

Multifunctional Natural Polymer Nanoparticles as Antifibrotic Gene Carriers for CKD Therapy

Backbone cationized highly branched poly( β -amino ester)s as enhanced delivery vectors in non-viral gene therapy

Targeted Activation of Cystic Fibrosis Transmembrane Conductance Regulator

Niclosamide - encapsulated lipid nanoparticles for the reversal of pulmonary fibrosis

Intranasal Delivery and Transfection of mRNA Therapeutics in the Brain Using Cationic Liposomes.

EGFP-EGF1-conjugated poly (lactic-co-glycolic acid) nanoparticles as a carrier for the delivery of CCR2− shRNA to atherosclerotic macrophage in vitro

Efficient mRNA delivery using lipid nanoparticles modified with fusogenic coiled-coil peptides

Lipid-based nanoparticles deliver mRNA to reverse the pathogenesis of lysosomal acid lipase deficiency in a preclinical model